我们急需更多的耐药性监控资源、更强的研发激励，以及确保普及精准诊断和品质医疗的创新性融资机制。
We urgently need more resources to monitor resistance, stronger incentives for R&D, and innovative financing mechanisms to ensure widespread access to accurate diagnoses and quality medicines.